<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500381</url>
  </required_header>
  <id_info>
    <org_study_id>4045-301</org_study_id>
    <nct_id>NCT02500381</nct_id>
  </id_info>
  <brief_title>Study of SRP-4045 and SRP-4053 in DMD Patients</brief_title>
  <acronym>ESSENCE</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053
      compared to placebo in Duchenne muscular dystrophy (DMD) patients with out-of-frame deletion
      mutations amenable to skipping exon 45 and exon 53, respectively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, multi-center study to evaluate the efficacy and
      safety of SRP-4045 and SRP-4053. Eligible patients with out-of-frame deletion mutations
      amenable to exon 45 or 53 skipping will be randomized to receive once weekly intravenous (IV)
      infusions of 30 mg/kg SRP-4045 or 30 mg/kg SRP-4053 respectively (combined-active group) or
      placebo for up to 96 weeks (the placebo-controlled period of the trial). This will be
      followed by an open label extension period in which all patients will receive open-label
      active treatment for up to 96 weeks.

      The study will enroll approximately 126 patients, with a planned minimum target of 45
      patients amenable to exon 45 skipping and 45 patients amenable to exon 53 skipping.

      Approximately 84 patients will be randomized to receive active treatment with either SRP-4045
      or SRP-4053 (depending on deletion mutation), and 42 patients will be randomized to receive
      placebo. Twice as many patients will receive active treatment as will receive placebo (2:1
      randomization).

      When approximately 75% of patients have been in the trial for 48 weeks, a group of
      independent experts will review key study results and will make a determination on whether
      patients will roll into the open-label period of the study and receive active drug or
      continue in the placebo-controlled period out to Week 96 as planned.

      Clinical efficacy will be assessed at regularly scheduled study visits, including functional
      tests such as the six-minute walk test (6MWT). All patients will undergo a muscle biopsy at
      baseline and a second muscle biopsy either at Week 48 or Week 96.

      Safety will be assessed through the collection of adverse events (AEs), laboratory tests,
      electrocardiograms (ECGs), echocardiograms (ECHOs), vital signs, and physical examinations
      throughout the study.

      Blood samples will be taken periodically throughout the study to assess the pharmacokinetics
      of both drugs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part 1 is double-blind and randomized; Part 2 is open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 96</measure>
    <time_frame>Baseline and Week 96</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dystrophin Protein Levels Determined by Western Blot at Weeks 48 or 96</measure>
    <time_frame>Baseline and Weeks 48 or 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Weeks 48 or 96</measure>
    <time_frame>Baseline and Weeks 48 or 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to Rise Independently From the Floor</measure>
    <time_frame>Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Loss of Ambulation (LOA)</measure>
    <time_frame>Baseline up to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score at Week 96</measure>
    <time_frame>Baseline and Week 96</time_frame>
    <description>The NSAA is a functional scale devised from the Hammersmith Scale of Motor Ability specifically for use in ambulant children with Duchenne muscular dystrophy (DMD). It consists of 17 activities graded 0 (unable to perform), 1 (performs with modifications), 2 (normal movement). The scale assesses activities required to remain functionally ambulant (example, rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA Total Score ranges from 0 to 34, with a score of 34 implying normal function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity Percent (FVC%) Predicted at Week 96</measure>
    <time_frame>Baseline and Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Frequency of Falls at Week 96</measure>
    <time_frame>Baseline and Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 96</measure>
    <time_frame>Baseline and Week 96</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>SRP-4045</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients amenable to exon 45 skipping will receive SRP-4045 intravenous (IV) infusions, weekly, at 30 mg/kg for up to 96 weeks in double-blinded period. This will be followed by an open label extension period in which all patients will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for up to 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRP-4053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in double-blinded period. This will be followed by an open label extension period in which all patients will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for up to 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by SRP-4045 or SRP-4053</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in double-blinded period. This will be followed by an open label extension period in which all patients will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV for up to 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP-4045</intervention_name>
    <description>SRP-4045 solution for IV infusion</description>
    <arm_group_label>SRP-4045</arm_group_label>
    <arm_group_label>Placebo followed by SRP-4045 or SRP-4053</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP-4053</intervention_name>
    <description>SRP-4053 solution for IV infusion</description>
    <arm_group_label>SRP-4053</arm_group_label>
    <arm_group_label>Placebo followed by SRP-4045 or SRP-4053</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SRP-4045 or SRP-4053 placebo-matching solution for IV infusion</description>
    <arm_group_label>Placebo followed by SRP-4045 or SRP-4053</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genotypically confirmed DMD, with genetic deletion amenable to exon 45 or exon 53
             skipping

          -  Stable dose of oral corticosteroids for at least 24 weeks

          -  Intact right and left biceps or 2 alternative upper muscle groups

          -  Mean 6MWT greater than or equal 300 meters and less than or equal to 450 meters

          -  Stable pulmonary and cardiac function: forced vital capacity (FVC) equal to or greater
             than 50% predicted and left ventricular ejection fraction (LVEF) greater than 50%

        Exclusion Criteria:

          -  Previous treatment with SMT C1100 (BMN-195) at any time

          -  Previous treatment with PRO045 or PRO053 within 6 months prior to Week 1

          -  Current or previous treatment with any other experimental treatment (other than
             deflazacort) within 12 weeks prior to Week 1

          -  Participation in any other DMD interventional clinical study within 12 weeks prior to
             Week 1

          -  Major surgery within 3 months prior to Week 1

          -  Presence of other clinically significant illness

          -  Major change in physical therapy regimen within 3 months prior to Week 1
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Lu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Mix, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>+1 888 727 3782</phone>
    <email>medinfo@sarepta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neuromuscular Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego/ UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine/Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>NW Florida Clinical Research Group, LLC</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Center for Integrative Rare Disease Research (CIRDR)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas, Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Las Vegas Clinic</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Clinical Research Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center (CCHMC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elke De Vos</last_name>
      <phone>﻿﻿+3293321954</phone>
      <email>elke.devos@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Nicolas Deconinck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Vanden Eynden</last_name>
      <phone>+3216343991</phone>
      <email>anne.vandeneynden@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Nathalie Goemans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Childrens Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Haig</last_name>
      <phone>(403) 955-3192</phone>
      <email>tiffany.haig@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Jean Mah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Bhullar</last_name>
      <phone>(519) 685-8500</phone>
      <phone_ext>55058</phone_ext>
      <email>gina.bhullar@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Craig Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha</city>
        <zip>15008</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela Hlozankova</last_name>
      <phone>﻿﻿+420224433367</phone>
      <email>m.hlozankova@centrum.cz</email>
    </contact>
    <investigator>
      <last_name>Jana Haberlová, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Des Enfants</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise Auriol</last_name>
      <phone>﻿+33534558589</phone>
      <email>auriol.f@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Claude Cances, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reference Centre for Neuromuscular Diseases</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle Peseux</last_name>
      <phone>﻿﻿+33240087880</phone>
      <email>christelle.peseux@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Yann Péréon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Duchêne</last_name>
      <phone>﻿﻿+33171738313</phone>
      <email>d.duchene@institut-myologie.org</email>
    </contact>
    <investigator>
      <last_name>Laurent Servais, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinna Seifert</last_name>
      <phone>﻿﻿+4920172385170</phone>
      <email>corinna.seifert@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Ulrike Schara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Wider</last_name>
      <phone>﻿﻿+4976127043440</phone>
      <email>sabine.wider@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Janbernd Kirschner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Blaschek</last_name>
      <phone>﻿﻿+4989440055110</phone>
      <email>astrid.blaschek@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Müller-Felber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of Israel</name>
      <address>
        <city>Petah Tikvah</city>
        <zip>49102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ori Raz</last_name>
      <phone>(972) 525-1860 x44</phone>
      <email>orira1@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Yoram Nevo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant' Anna</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda Fortunato</last_name>
      <phone>﻿﻿+393465374262</phone>
      <email>frtfnn@unife.it</email>
    </contact>
    <investigator>
      <last_name>Alessanda Ferlini, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genoa</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Pedemonte, MD</last_name>
      <phone>﻿﻿+3901056362675</phone>
      <email>marinapedemonte@gaslini.org</email>
    </contact>
    <investigator>
      <last_name>Claudio Bruno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az Ospedaliera Universitaria Policlinico G Martino</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Quattrocchi</last_name>
      <phone>﻿﻿+393493500123</phone>
      <email>danifour@alice.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Vita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>﻿00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariarosaria Vizzino</last_name>
      <phone>﻿﻿+390630158581</phone>
      <email>npi.clinicaltrials@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Eugenio Mercuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>﻿08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Vidal</last_name>
      <phone>﻿﻿+34935537115</phone>
      <email>nvidalf@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Jorge Diaz Manera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <zip>﻿08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Garcia</last_name>
      <phone>﻿﻿+34936009733</phone>
      <email>mgarciago@fsjd.org</email>
    </contact>
    <investigator>
      <last_name>Andres Nascimento, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Marti</last_name>
      <phone>﻿﻿+34961244000</phone>
      <email>mapifres@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Jesus Vilchez Padilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drottning Silvias Barn Och Ungdomssjukhus</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Lena Tulinius</last_name>
      <phone>﻿﻿+46313436069</phone>
      <email>anna-lena.tulinius@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Mar Tulinius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Rostron</last_name>
      <phone>﻿﻿+441133922344</phone>
      <email>heatherrostron@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Ann-Marie Childs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alder Hey Childrens Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Henderson</last_name>
      <phone>﻿﻿+441512525164</phone>
      <email>Timothy.Henderson@alderhey.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Stefan Spinty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital (GOSH)</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hinal Patel</last_name>
      <phone>020 7905 2639</phone>
      <phone_ext>2639</phone_ext>
      <email>hinal.patel@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Francesco Muntoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Corrall</last_name>
      <phone>﻿﻿+4401912084569</phone>
      <email>valerie.corrall@ncl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Volker Straub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>Exon Skipping</keyword>
  <keyword>DMD</keyword>
  <keyword>Exon 53</keyword>
  <keyword>Exon 45</keyword>
  <keyword>Ambulatory</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

